A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, double-blind, placebo-controlled, randomized Phase 3 trial to
assess the safety and efficacy of AXS-12 in narcoleptic subjects with cataplexy and excessive
daytime sleepiness (EDS).